The global prebiotic-fibre segment is surging as consumers look beyond basic gut health toward holistic benefits spanning metabolic, cardiovascular and even cognitive wellness.
In Europe alone, the prebiotic market was valued at $3.71 billion in 2024, is projected to reach $4.18 billion in 2025 and could climb to $10.77 billion by 2033 (at CAGR of approximately 12.6%).
Across the Atlantic, the US prebiotic-fibre segment stood at $1.45 billion in 2024, with forecasts predicting a rise to $2.35 billion by 2030 (CAGR ≈ 8.4%).
This double-digit growth underscores an urgent need for science-backed formulations that deliver proven multi-benefit functionality.1
Strategic alliance: exclusive distribution deal
To address this demand, SUANNUTRA, a global leader in nutraceutical ingredients serving more than 1500 customers in 60 countries, has inked an exclusive distribution agreement with Myota, the UK-based innovator behind the patented Metabolic Regulator prebiotic blend.
Under the partnership, SUANNUTRA secures rights to distribute Myota’s clinically validated formulations — including its flagship nine-fibre Metabolic Booster — throughout the US, UK and EU, with an official debut at Vitafoods Europe 2025 in Barcelona.
“The integration of Myota’s prebiotic blends into our scientifically endorsed portfolio enhances our ability to provide comprehensive health solutions,” says Anthony Weston, CEO of SUANNUTRA.
“With the increasing focus on metabolic health — especially in light of emerging microbiome-targeted approaches — our customers are looking for new solutions as standalone options or in synergy with our hero ingredient: Metabolaid.”
Technology spotlight: Metabolic Regulator Blend
Myota’s Metabolic Regulator combines nine plant-based fibres — gluten-free oat and wheat fibres, inulin, other fructo-oligosaccharides (FOSs), galacto-oligosaccharides (GOS) and resistant starch — that have been engineered to withstand gastric acidity and ferment selectively in the colon.
This targeted SCFA (short-chain fatty acid) production fortifies the gut lining and delivers the following systemic benefits:
- blood-sugar control: proprietary FDA-validated health claim for “contribution to healthy blood sugar control”2
- cholesterol and appetite regulation: clinical trials demonstrate reductions in LDL cholesterol and appetite hormones3
- digestive comfort: low-FODMAP formulation minimises bloating for sensitive individuals.4
“Backed by more than a decade of MIT-funded research and third-party clinical validation, our blend has shown efficacy in terms of improving post-prandial glucose response, lowering cholesterol and reducing systemic inflammation in metabolic-syndrome subjects,” explains Dr Thomas Gurry, CEO and cofounder of Myota.
Interview insights: NBR at Vitafoods Europe 2025
During Vitafoods Europe 2025 — the premier showcase for health innovations — Nutraceutical Business Review interviewed leaders from SUANNUTRA and Myota to understand the strategic vision and technical breakthroughs behind their alliance.
Their insights underscored both market opportunities and the collaborative spirit driving next-generation gut-centric solutions for 2025 and beyond.
NBR: Why choose Vitafoods Europe to unveil this partnership?
Jaime Durán (JD), Chief Business Officer for SUANNUTRA: Vitafoods Europe is where the industry’s most cutting-edge health innovations are launched each year.
In 2025, we’ve seen a flood of new solutions from advanced synbiotics to personalised prebiotic formulations. It was the perfect stage to introduce Myota’s Metabolic Regulator alongside our established Metabolaid platform.
NBR: How do your combined portfolios address the unmet needs of formulators and brands?
JD: Brands need clinically validated ingredients that deliver clear health benefits. By integrating Myota’s Metabolic Regulator (designed for targeted SCFA production) with our distribution network and regulatory expertise, we offer formulators a turnkey solution for metabolic support, immune modulation and gut-brain wellness.
NBR: What makes Myota the ideal partner for Suannutra’s metabolic health ambitions?
Dr Thomas Gurry (TG): Myota’s scientific rigour — from MIT-funded research and development (R&D) to independent clinical trials — ensures that our blends perform under real-world conditions.
We needed a partner who could communicate this science globally and ensure consistent quality. SUANNUTRA’s track record in personalised nutrition and global compliance made them the perfect choice.
NBR: Looking ahead, what innovations can we expect next from this alliance?
JD/TG: We are planning collaborative workshops at our R&D centres to explore codevelopment and tailor-made fibre profiles for specific microbiome imbalance, building on the momentum we saw at Vitafoods Europe 2025.
When asked about applications and future development, Jaime adds that Myota’s taste-free powder can be incorporated into a wide array of formats — from dietary supplements to functional foods — thereby leveraging insights from Myota’s existing B2C business.
Both companies also plan to run technical workshops to investigate opportunities such as synergistic trials combining Metabolaid and Myota’s prebiotic fibres.
As prebiotic fibres continue their double-digit growth — projected to outpace probiotics by 2027 — brands that can marry robust science with agile distribution will capture the lion’s share of a market hungry for next-generation gut-centric wellness.
The SUANNUTRA–Myota alliance exemplifies how strategic partnerships can accelerate innovation and market penetration in the fast-evolving prebiotic segment.
With launch activities kicking off at Vitafoods Europe 2025, industry observers will be watching how this collaboration reshapes expectations for scientifically grounded, multi-benefit prebiotic formulations in both Europe and North America.
References
- https://store.newhope.com/products/gut-health-report-2025.
- C.V. Hall, et al., “Effects of a Diverse Prebiotic Fibre Supplement on HbA1c, Insulin Sensitivity and Inflammatory Biomarkers in Prediabetes: A Pilot Placebo-Controlled Randomised Clinical Trial,” British Journal of Nutrition 132, 68–76 (2024).
- C.V. Hall, et al., “Effects of a Diverse Prebiotic Fibre Blend on Inflammation, the Gut Microbiota and Affective Symptoms in Metabolic Syndrome: A Pilot Open-Label Randomised Controlled Trial,” British Journal of Nutrition 132, 1002–10013 (2024).
- T. Gurry, et al., “Functional Heterogeneity in the Fermentation Capabilities of the Healthy Human Gut Microbiota,” PLOS One 16(7), e0254004 (2021).